secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001193125-25-024005
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Phase 1 INB-100: 100% AML remission at median 20.1 months, 100% 1-year PFS/OS
--------------------------------------------------------------------------------

- All 9 AML patients remain in complete remission; median follow-up 20.1 months, longest >3 years.
- One-year PFS/OS 100% vs historical controls (CIBMTR PFS 67.8%, OS 74.7%).
- No cytokine release syndrome or neurotoxicity observed; manageable GvHD in line with historical data.
- Patients median age 68, high-risk, including prior CAR-T failures; therapy well-tolerated.
- Company to host conference call today at 8:30am ET to discuss data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525024005/0001193125-25-024005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525024005/d905966d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-024005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer